Clinical Trials Logo

Brain Death clinical trials

View clinical trials related to Brain Death.

Filter by:

NCT ID: NCT02635347 Completed - Clinical trials for Carcinoma, Hepatocellular

Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study

Start date: November 2015
Phase: N/A
Study type: Interventional

This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT). Remote ischemic conditioning will consist of 3 cycles of 5 minutes of lower limb ischemia induced via a mid-thigh pneumatic tourniquet, followed by 5 minutes of reperfusion. Interventions will take place after anesthesia induction but before surgery, at the completion of the procedure, and on the mornings of post-operative days 1-4.

NCT ID: NCT02581111 Completed - Clinical trials for Lung Transplantation

Naloxone for Optimizing Hypoxemia Of Lung Donors

NO-HOLDS
Start date: September 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Brain-dead patients who provide authorization for organ donation will be randomized to naloxone or placebo if baseline arterial blood gas (ABG) after initiation of OPO (Organ Procurement Organization) management reveals hypoxemia, as defined by the ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) below 300 mm Hg, unless they have already been ruled-out for lung recovery. Investigators aim to assess whether naloxone improves oxygenation prior to organ recovery more than placebo.

NCT ID: NCT02525510 Completed - Brain Death Clinical Trials

Deceased Organ Donor Interventions to Protect Kidney Graft Function

Start date: July 26, 2017
Phase: N/A
Study type: Interventional

To protect kidney function during the transplantation process by comparing mild hypothermia in the deceased organ donor before organs are recovered and pulsatile perfusion of the kidney after recovery and prior to transplantation.

NCT ID: NCT02503813 Completed - Brain Death Clinical Trials

Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?

Start date: July 2015
Phase: N/A
Study type: Interventional

One required examination for declaration of death by neurological criteria is the apnea challenge test. The apnea challenge test evaluates the medulla brainstem respiratory center response to a rise in CO2. The current guideline requires arterial sampling of CO2 and therefore either arterial puncture or arterial catheter placement for the examination. Arterial catheter is an invasive monitoring device and is not without complications. Recent studies have demonstrated that there is a direct correlation between peripheral venous and arterial blood gas measures and that peripheral venous CO2 measures may be used as alternatives to arterial CO2 measure.The purpose of this study is to evaluate brainstem response during the apnea challenge test to a rise in venous CO2 and correlate it with the rise in arterial measured CO2. The objective of this study is to demonstrate a similar rise between the venous and arterial CO2 during the apnea challenge test and eliminate the necessity of arterial blood sampling for the sole purpose of apnea challenge test in the future.

NCT ID: NCT02483273 Completed - Brain Death Clinical Trials

Alterations of Conjunctival Microcirculation in Brain Dead Patients

Start date: May 2011
Phase: N/A
Study type: Observational

Study hypothesize that ocular microcirculation is reflecting cerebral perfusion. The purpose of this study is to evaluate ocular microcirculation in brain dead patients using side dark field (SDF) videomicroscope and compare it with microcirculatory parameters of healthy volunteers.

NCT ID: NCT02460250 Completed - Clinical trials for Liver Transplantation

Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death

FIBROSCAME
Start date: February 2015
Phase: N/A
Study type: Interventional

According to the French Biomedicine Agency annual report on retrieval activities and transplants, 1,164 liver transplants were performed in 2011 and 1,161 in 2012. If the amount of brain death donors and retrieved liver grafts appears relatively stable, it remains clearly insufficient compared to the increasing number of patients on the waiting list for liver transplantation (2,462 in 2011). The median time on the waiting list before liver transplantation which was established from the cohort of patients registered between 2007 and 2011 (excluding patients registered for emergency transplantation and for living related-donor transplantation) increased significantly from 4.4 months between 2007 and 2009 to 6.6 months between 2010 and 2011. In order to compensate for the lack of liver grafts, donors acceptance criteria were broadened. For example, alternative transplantation lists were created with liver grafts coming from so-called "marginal" donors. However, despite these efforts, livers were retrieved on only two out of three brain death donors, i.e. in 1,572 and 1,589 organ donors in 2011 and 2012, respectively. This is unfortunately not enough to meet the increasing needs in liver grafts and a growing number of patients wait each year for transplant. Strategic lines of improvement were defined in order to meet the "2012-2016 transplant perspective" which targets 5,700 transplants carried out in 2015 (+5% every year, all transplants included, with 5,023 transplants in 2012). According to the last consensus conference on liver transplantation of the HAS (French High Authority of Health) the assessment of the degree of macrovacuolar and microvacuolar steatosis determines the possibility to retrieve the graft or not. Liver steatosis consists in an accumulation of fatty droplets in hepatocytes. Its prevalence is high, ranging from 16% to 31% in the general population, and increases up to 46% in heavy drinkers and to 50-80% in the obese population. Steatosis results mostly from alcohol consumption and from metabolic syndrome (obesity, type 2 diabetes, hypertriglyceridemia) called non-alcoholic fatty liver disease (NAFLD), and is more rarely secondary to viral hepatitis or exposure to certain medications. NAFLD involves up to 30% of the population in Western countries and its prevalence is increasing. NAFLD may lead to asymptomatic steatosis, but also to steatohepatitis or advanced fibrosis including cirrhosis and its complications Accordingly, the improvement of liver grafts selection based on objective quantitative criteria which takes into account the degree of liver steatosis appears crucial to increase the number of hepatic transplants.

NCT ID: NCT02211053 Terminated - Clinical trials for Brain Dead Organ Donors

Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial

ECHOT4
Start date: July 2014
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the feasibility of a randomized controlled trial comparing levothyroxine to placebo in neurologically deceased donors

NCT ID: NCT02102945 Recruiting - Brain Death Clinical Trials

Special Imaging Technique to Aid in the Diagnosis of Patients in Coma After Cardiac Arrest

Start date: May 2014
Phase: N/A
Study type: Interventional

In the present pilot study, the investigators propose to determine if performing CT perfusion scans in post-cardiac arrest patients in coma will help prognosticate the outcome in these patients.

NCT ID: NCT02045407 Completed - Brain Death Clinical Trials

Computed Tomography Angiography Accuracy in Brain Death Diagnosis

Start date: January 2014
Phase:
Study type: Observational

The purpose of this study is to assess the reliability of computed tomography angiography (CTA) to diagnose brain death, face of several conditions that make impossible to define such diagnosis using clinical criteria exclusively.

NCT ID: NCT01967953 Completed - Brain Death Clinical Trials

Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation

EVLP_MI
Start date: January 2011
Phase: Phase 1
Study type: Interventional

The recent introduction of ex-vivo lung perfusion (EVLP) as a tool to evaluate and recondition lungs from marginal donors has opened a new era in the field of lung transplantation.